Daina Graybosch
Stock Analyst at Leerink Partners
(1.30)
# 3,531
Out of 5,182 analysts
93
Total ratings
41.18%
Success rate
-6.87%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Daina Graybosch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IPSC Century Therapeutics | Downgrades: Market Perform | $7 → $2 | $2.31 | -13.42% | 5 | Nov 17, 2025 | |
| IPHA Innate Pharma | Downgrades: Market Perform | $10 → $2 | $1.44 | +38.89% | 11 | Sep 18, 2025 | |
| XLO Xilio Therapeutics | Initiates: Outperform | $28 | $8.32 | +236.54% | 1 | Aug 6, 2025 | |
| ADAG Adagene | Initiates: Outperform | $7 | $3.82 | +83.25% | 1 | Aug 6, 2025 | |
| SMMT Summit Therapeutics | Initiates: Underperform | $12 | $16.12 | -25.54% | 1 | Jun 11, 2025 | |
| MRK Merck & Co. | Maintains: Outperform | $136 → $119 | $112.16 | +6.10% | 19 | Jan 13, 2025 | |
| BOLT Bolt Biotherapeutics | Downgrades: Market Perform | $60 → $20 | $5.06 | +295.26% | 8 | May 15, 2024 | |
| NKTR Nektar Therapeutics | Maintains: Market Perform | $75 → $45 | $86.46 | -47.95% | 10 | Feb 24, 2023 | |
| FATE Fate Therapeutics | Maintains: Outperform | $62 → $10 | $1.53 | +553.59% | 7 | Jan 6, 2023 | |
| RCUS Arcus Biosciences | Maintains: Outperform | $40 → $38 | $25.68 | +47.98% | 2 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $30 → $8 | $4.24 | +88.68% | 4 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $223 → $224 | $97.54 | +129.65% | 16 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $2.93 | +923.89% | 1 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $17 | $0.72 | +2,251.31% | 3 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $9 | $2.71 | +232.10% | 4 | Feb 25, 2022 |
Century Therapeutics
Nov 17, 2025
Downgrades: Market Perform
Price Target: $7 → $2
Current: $2.31
Upside: -13.42%
Innate Pharma
Sep 18, 2025
Downgrades: Market Perform
Price Target: $10 → $2
Current: $1.44
Upside: +38.89%
Xilio Therapeutics
Aug 6, 2025
Initiates: Outperform
Price Target: $28
Current: $8.32
Upside: +236.54%
Adagene
Aug 6, 2025
Initiates: Outperform
Price Target: $7
Current: $3.82
Upside: +83.25%
Summit Therapeutics
Jun 11, 2025
Initiates: Underperform
Price Target: $12
Current: $16.12
Upside: -25.54%
Merck & Co.
Jan 13, 2025
Maintains: Outperform
Price Target: $136 → $119
Current: $112.16
Upside: +6.10%
Bolt Biotherapeutics
May 15, 2024
Downgrades: Market Perform
Price Target: $60 → $20
Current: $5.06
Upside: +295.26%
Nektar Therapeutics
Feb 24, 2023
Maintains: Market Perform
Price Target: $75 → $45
Current: $86.46
Upside: -47.95%
Fate Therapeutics
Jan 6, 2023
Maintains: Outperform
Price Target: $62 → $10
Current: $1.53
Upside: +553.59%
Arcus Biosciences
Nov 3, 2022
Maintains: Outperform
Price Target: $40 → $38
Current: $25.68
Upside: +47.98%
Aug 29, 2022
Downgrades: Market Perform
Price Target: $30 → $8
Current: $4.24
Upside: +88.68%
Jul 29, 2022
Maintains: Outperform
Price Target: $223 → $224
Current: $97.54
Upside: +129.65%
Jul 18, 2022
Initiates: Outperform
Price Target: $30
Current: $2.93
Upside: +923.89%
May 11, 2022
Maintains: Outperform
Price Target: $18 → $17
Current: $0.72
Upside: +2,251.31%
Feb 25, 2022
Maintains: Outperform
Price Target: $16 → $9
Current: $2.71
Upside: +232.10%